Background: The elderly are more often referred to nephrologists and questions about indications for renal biopsy are increasing. The vascular lesions that appear with aging make the diagnosis of additional nephropathy more difficult. The purpose of our study is to investigate the characteristics of renal biopsies in the elderly in order to evaluate the indications and their use in guiding specific therapeutic interventions.
Introduction
Since vascular lesions often develop in the kidney with age, and complicate the often present glomerulosclerosis of aging 1 , the clinical diagnosis of glomerulopathy might be more difficult in the elderly and require histological assessment of renal structure. In this retrospective study, we investigated specific characteristics of aging patients undergoing renal biopsy, particularly those with the nephrotic syndrome, in order to evaluate the indications for renal biopsy and evaluate current treatments in the population of elderly patients.
The indications for renal biopsy in the elderly are increasing. In Japan, a recent study showed that 15.1% of patients undergoing a renal biopsy in 2005 were more than 65 year old, compared to 8.2% in 1995 2 . In Italy, one centre reported that 38% of the biopsied patients are now more than 65 year old 3 and in United Kingdom, 12% of kidney biopsies were done in patients over the age of 60 in 1978 to 30% in 1990 1 . In western France, a unique study reported that mean age for renal biopsy in 1976 was 35 years and 52 years in 2000 4 . These modifications could be explained in part by the increase in longevity, but also by the improvements of physiological health status in aging. Thus, the indications to kidney biopsy and/or specific treatments in elderly may need to be re-evaluated.
Why might renal biopsy be informative in aging patients? First, the clinical presentation is often confusing in the elderly because of multiple associated conditions. For instance, the clinical presentation of acute renal disease, requiring specific treatment, may be unusual superimposed on a chronic vascular or diabetic nephropathy 5 . Secondly, kidney biopsy may be more risky than at a younger age, due to cortical atrophy, and the co administration of anticoagulant or anti-platelet therapy due to cardiovascular disease.
However, a few studies have shown that the incidence of complications in the elderly is not greater than that in younger patients [6] [7] [8] . Finally, specific treatment for glomerulopathy is often based on corticotherapy and/or immunosuppressive drugs which have serious side effects.
Thus, giving them to an elderly patient without a biopsy-proven diagnosis may not be acceptable. On the other hand, not giving the appropriate therapy to "physiologically-young
elderly" who would benefit would also be unacceptable 2, 6, 9-11 .
In any event, consideration for performing a kidney biopsy must include careful checking for contra-indications: small kidneys, anticoagulant or antiplatelet therapy, bleeding disorders, uncontrolled hypertension or inability to remain recumbent for a few hours.
The objective of this study was to determine if our kidney biopsy policy in nephrotic elderly patients led to a diagnosis without an unacceptable complication rate. And that this diagnosis led to a specific treatments permitting improvements in renal function and patient survival. Our policy for renal biopsies in aged patients includes the following indications:
proteinuria with extra-renal signs suggestive of systemic disease; nephrotic syndrome in absence of long history of diabetes or established amyloidosis; acute renal failure without evident explanation or rapid regression, unexplained chronic renal failure. However, to our mind, renal biopsy is not indicated in elderly patients with well-documented, slowly progressive renal insufficiency.
For this purpose, we retrospectively analyzed all the kidney biopsies done in patients over the age of 70 years, with a focus on treatment and prognosis of those presenting with nephrotic syndrome. We chose this focus since most of the articles in the literature examined the indications and results of renal biopsy 2, 3, 9, 12-14 15 , but very few examined the follow-up after specific treatments.
Materials and methods

Methods
Using Immunofluorescence staining was graded on a scale of 0 to 3+. by Kaplan Meier analysis using XLSTAT®.
Statistics
Results
From the 1 st of January 2000 to the 31st of December 2007, 157 patients, aged more than 70 years underwent renal biopsy; 6 were excluded because the biopsy was done on a transplanted kidney and one because it was done on a tumor, leaving a total of 150 patients.
Characteristics of the population
The mean number of kidneys biopsied was 18. -chronic renal failure with proteinuria and/or hematuria:8% -proteinuria and/or hematuria with normal renal function: 5%.
Histological diagnosis
Ninety one (61%) out of the 150 patients had a glomerulopathy, 35 (23%) a tubulointerstitial nephropathy, 18 (12%) a vascular nephropathy and for 7 (4.6%) patients no diagnosis could be made (Table 1) . Pauci-immune crescentic glomerulonephritis (PICGN) with rapidly progressive renal failure (with or without nephritic syndrome) was the most common glomerulopathy (37%). Most patients with vascular nephropathy had benign nephroangiosclerosis. Finally, the leading cause of tubulointerstitial nephropathy was drug toxicity, especially after fluindione treatment (4 /13 cases).
Renal biopsy complications
Kidney biopsy was done under radiological control. Only 5 (3.3%) patients presented benign biopsy complications; two patients developed a hematoma which did not require blood transfusion, three developed a hematoma requiring blood transfusion and one had macroscopic hematuria requiring vesical lavages. to 831 µmol/L) the day of biopsy; GFR estimated by MDRD was more than 60 ml/min for 14 (31%) patients, between 30 and 60 ml/min for 13 (29%) patients, between 15 and 30 ml/min for 10 (22%) patients and less than 15 ml/min for 8 (18%) patients.
Renal histology
The histological diagnosis of nephrotic patients (figure 1) revealed that, surprisingly, the 2 leading diagnoses were MPGN (9 patients, 20%), and MCD (9 patients, 20%) ( Table 2 ).
All of the MPGN were type 1, all had microscopic hematuria and almost all (8 out of All the MCD were primary and no associated neoplasia was detected during the current hospitalization or follow-up. Surprisingly, 6 out of 9 (66%) of those patients had microscopic hematuria at the time of the biopsy. In addition, 7 out of these 9 patients had both glomerular changes and significant tubulointerstitial lesions.
All the MN were idiopathic.
All 6 patients with amyloidosis had AL amyloidosis: 4 were associated with MGUS, 1 was secondary to a myeloma and one patient had Waldenstrom's disease. The kidney biopsy was done to investigate nephrotic syndrome in all of those patients and the diagnosis of amyloidosis was made with the help of the biopsy.
Nephrotic syndrome complications
Almost all patients (82%) had edema at the time of diagnosis and 61% had dyslipidemia. However, only 3 (6.7%) developed venous thrombosis during the follow up.
All of them had MN, with serum albumin levels above 20g/L. On the contrary, several patients without MN and with serum albumin levels below 20 g/L did not have preventive anticoagulation and did not develop venous thrombosis.
Treatment and complications
Twenty-nine nephrotic patients were treated, there were no difference for sex (p=0.74), and the median age was (77.5 vs 78.5 years) between the treated and non-treated group. There was no major difference in terms of nephropathy between both groups: 6 MPGN in the treated group vs 9 in the non treated , MCD(8 vs 9), FSGS (3 vs 4) ,
amyloidosis (4 vs 6) and RPGN (4 vs 4) except for MN (1 vs 7).
Almost half of the patients (47%) received ACEi or ARB during follow-up to treat hypertension and/or proteinuria. As for specific glomerulonephritis treatments, 25 (86%) nephrotic patients received steroids and 64% received various immunosuppressive regimens (cyclophosphamide, cyclosporine, melphalan, gammaglobulins or rituximab) in addition to steroids (table 3) . Eighteen (62%) treated patients developed therapeutic complications: 17 infections (9 bacterial, 7 viral, and one pneumocystosis), 8 psychiatric disorders, 5 bone disorders, 4 diabetes and 3 adrenal insufficiency after stopping the steroids. One death was directly linked to treatment due to a septic shock during the period of bone marrow suppression.
Renal and overall Survival
Of the 29 patients treated with steroids and/or immunosuppressive drugs, 16 (55%) achieved complete remission, and 10 (34%) did not and 3 relapsed after stopping the therapy.
Out of the 16 untreated patients, 4 (25%) presented with spontaneous remission, and 1 (6%) relapsed after initial spontaneous remission. In total, there was a significantly larger number of remissions after treatment (p=0.0345).
Renal function remained stable in 36% patients, improved in 31% and decreased in 33%, all of whom presented with severe renal failure at the time of biopsy.
At day 1000, survival was significantly better in the treated group than in the untreated group (p=0.0227) (figure 1). The most important factor influencing survival was initial renal function (p=0.0042). Interestingly, neither persistence of nephrotic syndrome nor treatment complications influenced overall survival. In addition, the mortality rate was higher in the amyloidosis group (83%) than in the MCD group (11%).
Discussion
This retrospective study revealed that performing renal biopsies in selected elderly patients is safe and useful in establishing a precise diagnosis for elaborating appropriate treatment strategies.
The first interesting conclusion drawn from this study, was the unusual clinical presentation of many patients, as had previously been described 9, 17, 18 . Many of them, except patients with amyloidosis, had high blood pressure and/or hematuria and/or renal failure, even with MCD nephropathy. MCD is thought to present as a pure nephrotic syndrome, defined by the absence of hematuria, renal failure or hypertension. Preexisting hypertension or even glomerulosclerosis can confuse the clinical presentation 19 . On the other hand, 25% of MN patients did not have hematuria, which is a classical clinical symptom of MN. This statement confirms the importance of renal biopsy in the elderly for establishing a specific diagnosis and in helping direct subsequent treatment.
The second interesting finding is the presentation of those patients and their nephropathies. Some patients were more than 80, even 90 years old. The gender ratio was 33% men and 67% women, which is expected for those ages. The indication for renal biopsy resembled previous published cohorts: ~30% presented with nephrotic syndrome and 30%
with acute renal failure 1, 2, 9, 12, 14, 17, 20 . However, the histological diagnoses were more variable. Renal drug toxicity is often thought to be a frequent cause of renal failure, especially in elderly patients, but represented only few cases in our population. We were not able to determine if it was a rare event or if it was not an indication for renal biopsy. As RPGN is the leading cause of renal biopsy in the elderly, it was much more frequent in this elderly population than in younger patients 9 . Contrary to the literature 21 , secondary MCD and MN were rare compared to idiopathic MCD and MN even if underlying etiologies were rigorously and systematically investigated. The elevated rate of MPGN in our cohort was surprising, and contrasted with the small number reported in the literature 1, 9 . Furthermore, the MPGN patients did not have an underlying infectious etiology. Many patients with monoclonal gammapathies were identified, suggesting that MPGN due to hematologic disorders may be more frequent at least in Europe, than those due to infectious diseases.
Biopsy or not biopsy?
This study also revealed that, if contraindications are respected and indications well controlled, kidney biopsy is a simple and worthwhile tool, almost always providing a diagnosis, and is associated with few complications 9 . A diagnosis could not be histologically established in only 4.7%, and only 3.3% of the patients presented with complications most of which were minimal. It does not look that different from the general population, since lifethreatening complications occur in less than 0.1% of biopsies and bleeding occurs in up to 13%, 6 to 7% needing for therapeutic interventions 22 .
Finally, our study suggests that aggressive therapy, even immunosuppressive therapy can be performed in old, and even very old patients, without an unacceptable rate of complications, especially infectious complications.
We understand that our study has several limits. It is a retrospective observational study but there is no large prospective nor retrospective geriatric cohort in the literature.
Even the comparison between the treated and untreated groups should be carefully evaluated.
First of all, the patients were carefully selected prior to biopsy, and secondly, nephrologists do not see all the elderly patients with renal disorders, even nephrotic syndrome. General practitioners may have selected the patients and referred only those aged patients with relatively good general status to the specialist. In addition, nephrologists only perform biopsies in aged patients who can bear the biopsy and a potential treatment. Most believe it is unnecessary to take the risk of biopsying a frail patient who cannot undergo post-biopsy treatment. The only conclusion to be made from the survival data is that treatment for nephropathy, even including steroids or other immunosuppressive therapy, was not deleterious for this group of selected elderly patients.
Conclusion
In conclusion, this study, like the recent published data of Moutzouris 15 showed that renal biopsy is feasible and may be indicated in elderly patients, as long as contra-indications are respected. Histological diagnosis is necessary to clarify a clinical situation, confused by previous co-morbidities and may help clinicians to choose the appropriate therapeutic intervention. Glomerulonephritis in the elderly is not uncommon, often difficult to diagnose without histology, and often requires specific and sometimes aggressive therapies. 
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